Cancer Stem Cell News Volume 12.13 | Apr 5 2023

    0
    223








    2023-04-05 | CSCN 12.13


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 12.13 – 5 April, 2023
    TOP STORY

    Aberrant Cell State Plasticity Mediated by Developmental Reprogramming Precedes Colorectal Cancer Initiation

    Using genetically engineered and carcinogen-induced mouse models of intestinal neoplasia, scientists observed that impaired differentiation was a conserved event preceding cancer development.
    [Science Advances]

    Full ArticlePress Release
    Find the Right Antibodies for Your Stem Cell Research. Learn More
    PUBLICATIONSRanked by the impact factor of the journal

    A Self-Propagating C-Met-SOX2 Axis Drives Cancer-Derived IgG Signaling That Promotes Lung Cancer Cell Stemness

    The sialylated cancer IgG (SIA-cIgG)/c-Met/SOX2/SIA-cIgG signaling loop was highly active in stem-like cells from many epithelial cancers and was crucial for cancer stemness in vitro and in vivo.
    [Cancer Research]

    Abstract

    Tespa1 Facilitates Hematopoietic and Leukemic Stem Cell Maintenance by Restricting c-Myc Degradation

    Researchers observed that the expression of thymocyte-expressed, positive selection-associated 1 (Tespa1) was markedly increased in hematopoietic stem cells after stress exposure.
    [Leukemia]

    Full Article

    eIF2Bδ Blocks the Integrated Stress Response and Maintains eIF2B Activity and Cancer Metastasis by Overexpression in Breast Cancer Stem Cells

    Scientists described a unique translation regulatory axis enacted by reduced expression of miR-183 in breast CSCs, which they showed targeted the eIF2Bδ subunit of guanine nucleotide exchange factor eIF2B.
    [Proceedings Of The National Academy Of Sciences Of The United States Of America]

    Abstract

    Development of a Synthetic, Injectable Hydrogel to Capture Residual Glioblastoma and Glioblastoma Stem-Like Cells with CXCL12-mediated Chemotaxis

    Investigators developed a thiol-Michael addition injectable hydrogel further to capture glioblastoma/glioblastoma stem-like cells through CXCL12-mediated chemotaxis.
    [Advanced Healthcare Materials]

    Abstract

    oHSV-P10 Reduces Glioma Stem Cell Enrichment after Oncolytic HSV Therapy

    Researchers showed that post-oncolytic HSV (oHSV) virotherapy-activated AKT signaling results in an enrichment of glioblastoma stem-like cell signatures in glioma.
    [Molecular Therapy Oncolytics]

    AbstractFull ArticleGraphical Abstract

    The Regulatory Effect of the YY1/miR-HCC2/BAMBI Axis on the Stemness of Liver Cancer Cells

    Investigators evaluated novel regulators of stem cell factor expression to identify novel therapeutic strategies that could target liver CSCs.
    [International Journal Of Oncology]

    Abstract

    The Evaluation of Tumorigenicity and Characterization of Colonies in a Soft Agar Colony Formation Assay Using Polymerase Chain Reaction

    A soft agar colony formation assay using polymerase chain reaction method was applied to evaluate tumorigencitiy of cells in cellular therapy products.
    [Scientific Reports]

    Full Article

    Culture of Circulating Tumor Cells Using a Microfilter Device

    The authors established a novel approach to capture and cultivate circulating tumor cells (CTCs) using a microfilter device. Whole blood was filtered to isolate CTCs and cells captured on the microfilter were cultured in place.
    [Oncology Reports]

    Abstract
    Be sure the cells you’re gene editing are still HSPCs with StemSpan™ SFEM II culture medium.
    REVIEWS

    Cancer Stem Cell-Derived Exosome-Induced Metastatic Cancer: An Orchestra within the Tumor Microenvironment

    Scientists summarize the characteristic features and functional mechanisms of CSC-derived exosomes/mesenchymal stem cell exosomes/cancer-associated fibroblast exosomes and their mutual impact on cancer progression and therapy resistance.
    [Biochimie]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    FDA Converts to Full Approval Indication for Keytruda® (Pembrolizumab) for Certain Adult and Pediatric Patients with Advanced Microsatellite Instability-High (Msi-H) or Mismatch Repair Deficient (dMMR) Solid Tumors

    Merck announced that the US FDA has granted full approval to KEYTRUDA for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.
    [Merck]

    Press Release
    FEATURED EVENT

    World Oncology Cell Therapy Congress

    April 25 – 26, 2023
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scholar – Immunotherapy for Glioblastoma

    University of Southern California – Los Angeles, California, United States

    Postdoctoral Position – Cancer Metabolism, Epigenetics, Hematopoiesis

    University of Texas Health Science Center – San Antonio, Texas, United States

    Staff Scientist – Molecular and Cellular Mechanisms of Breast Cancer Initiation

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Fellow – Tumor Suppressor p53

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    Associate Research Scientists – Cancer Genetics

    Columbia University – New York, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter